![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sinopharm COVID-19 Shots Show Little Efficacy Against Omicron Subvariants
Sinopharm COVID-19 Shots Show Little Efficacy Against Omicron Subvariants
Sinopharm’s two-dose COVID-19 vaccine series did not produce significant antibody responses against Omicron subvariants, according to a small Chinese study reported in the journal Lancet Infectious Diseases.
Based on data from 25 participants, the shots’ neutralizing antibodies against a range of Omicron subvariants were either not detectable or they were only minimally detectable, the researchers said.
However, the doses produced a detectable neutralizing response against the spike protein mutation D614G in 84 percent of individuals. The mutation emerged early in the pandemic and quickly became the dominant circulating strain.
Upcoming Events
-
18Jul
-
21Oct